The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate ...

The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and ...

The US gene therapy company Regenxbio and the Japanese firm Nippon Shinyaku have joined forces to boost the development and commercialization of Regenxbio’s gene therapies RGX-121 for the treatment of ...

The Swiss drug development company Windward Bio recently announced that it had officially launched with a $200 million Series ...